Korean J Fam Pract. 2018; 8(1): 47-51  https://doi.org/10.21215/kjfp.2018.8.1.47
The Effect of Colonoscopy on the Diagnosis of Impaired Fasting Glucose in Health Examination Subjects
Na-Rae Kim1, Jae-Seok Im1, Yong-Jin Cho1,*, Sung-Ho Hong2, Choo-Yon Cho2, Jung-Eun Oh1, Byung-Wook Yoo2, Kyung-Suk Shin3, Hyun Joe2, Hwang-Sik Shin1, Doo-Yong Son3
1Department of Family Medicine, Cheonan Hospital, Soon Chun Hyang University College of Medicine, Cheonan; 2Department of Family Medicine, Seoul Hospital, Soon Chun Hyang University College of Medicine, Seoul; 3Department of Family Medicine, Gumi Hospital, Soon Chun Hyang University College of Medicine, Gumi, Korea
Yong-Jin Cho
Tel: +82-41-570-2238, Fax: +82-41-574-7792
E-mail: jyjfm@schmc.ac.kr
ORCID: http://orcid.org/0000-0002-5932-1138
Received: March 9, 2017; Revised: July 24, 2017; Accepted: August 11, 2017; Published online: February 20, 2018.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Early diagnosis of impaired fasting glucose (IFG) is important because 15%–30% of IFG patients are known to progress to diabetes mellitus in 5 years. In this study, patients were classified into two groups as follows: patients who underwent colonoscopy and who did not. We compared fasting glucose and glycated hemoglobin A1c (HbA1c) levels between the two groups. The fasting glucose levels of the subjects from each group whose HbA1c levels were between 5.7% and 6.4% were identified to determine how colonoscopy affects their fasting glucose levels.
Methods: The physical assessments, fasting glucose levels, and HbA1c levels of 19,707 patients who visited a Health Promotion Center were examined, and the subjects were divided into 3 subgroups according to HbA1c level (≤5.6%, 5.7%–6.0%, and ≥6.1%). Then, we compared fasting glucose levels between the colonoscopy and non-colonoscopy groups.
Results: The colonoscopy group showed a significant decrease in mean fasting glucose level in comparison with the non-colonoscopy group. The patients in the subgroups with HbA1c levels of ≤5.6% and 5.7%–6.0% who underwent colonoscopy presented significantly decreased fasting glucose levels. However, no significant difference was observed in the ≥6.1% subgroup.
Conclusion: We confirmed that the two subgroups with HbA1c levels of ≤5.6% and 5.7%–6.0% tended to exhibit decreased fasting glucose levels by prolonged fasting time according to performing colonoscopy, failing to diagnose IFG precisely. Therefore, we recommend to examine the HbA1c level on the day performing colonoscopy or to measure the fasting glucose level on another day to diagnose IFG.
Keywords: Colonoscopy; Glycated Hemoglobin A1c; Health Promotion; Impaired Fasting Glucose
  1. Chun KH. Evidence-based management and treatment of high-risk individuals with pre-diabetes. J Korean Med Assoc 2011; 54: 1020-7.
  2. Korean Diabetes Association. Diabetes Fact Sheet in Korea 2016 [Internet]. Korean Diabetes Association (KR): c2011. [cited 2017 Feb 20].
  3. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 [Internet]. Atlanta (GA): US Department of Health and Human Services. [cited 2017 Feb 20].
  4. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 Suppl 1: S5-20.
    Pubmed CrossRef
  5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 Suppl 1: S62-9.
    Pubmed KoreaMed CrossRef
  6. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-34.
    Pubmed KoreaMed CrossRef
  7. Emberson JR, Whincup PH, Walker M, Thomas M, Alberti KG. Biochemical measures in a population-based study: effect of fasting duration and time of day. Ann Clin Biochem 2002; 39: 493-501.
    Pubmed CrossRef
  8. Gerich JE. Physiology of glucose homeostasis. Diabetes Obes Metab 2000; 2:345-50.
    Pubmed CrossRef
  9. Spiegel K, Tasali E, Leproult R, Van Cauter E. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol 2009; 5: 253-61.
    Pubmed KoreaMed CrossRef
  10. Finlayson C, Zimmerman D. Hyperglycemia not due to diabetes mellitus. Clinical Pediatric Emergency Medicine 2009; 10: 252-5.
  11. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016; 355: i5953.
    Pubmed KoreaMed CrossRef
  12. Mijajlović MD, Aleksić VM, Šternić NM, Mirković MM, Bornstein NM. Role of prediabetes in stroke. Neuropsychiatr Dis Treat 2017; 13: 259-67.
    Pubmed KoreaMed CrossRef
  13. Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991; 34: 891-8.
    Pubmed CrossRef
  14. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses’ Health Study. Am J Epidemiol 1997; 145: 614-9.
    Pubmed CrossRef
  15. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOPNIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
  16. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150-6.
    Pubmed CrossRef
  17. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
    Pubmed KoreaMed CrossRef
  18. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105.
  19. Hulmán A, Færch K, Vistisen D, Karsai J, Nyári TA, Tabák AG, et al. Effect of time of day and fasting duration on measures of glycaemia: analysis from the Whitehall II Study. Diabetologia 2013; 56: 294-7.
    Pubmed CrossRef
  20. Rex DK, McGowan J, Cleveland Mv, Di Palma JA. A randomized, controlled trial of oral sulfate solution plus polyethylene glycol as a bowel preparation for colonoscopy. Gastrointest Endosc 2014; 80: 482-91.
    Pubmed CrossRef
  21. Morselli L, Leproult R, Balbo M, Spiegel K. Role of sleep duration in the regulation of glucose metabolism and appetite. Best Pract Res Clin Endocrinol Metab 2010; 24: 687-702.
    Pubmed KoreaMed CrossRef

This Article

Author ORCID Information

Social Network Service